Liver disease - Significant improvement with lamivudine

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 380-385

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chronic hepatitis B; Liver histology; Nucleoside analogue; Treatment; YMDD variant

Indexed keywords

LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; NONHUMAN; VIREMIA;

ANTIVIRAL AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; TREATMENT OUTCOME;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034044452     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<380::AID-JMV17>3.0.CO;2-5     Document Type: Article

References (20)

1. Boag F. 1991. Hepatitis B: heterosexual transmission and vaccination strategies. Int J Sex Trans Dis AIDS 2:318-324.
2. Chang C-N, Skalski V, Zhou JH, Cheng Y-C. 1992. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 267:22414-22420.
3. Davey S. 1996. State of the world's vaccines and immunisation. Geneva: World Health Organisation, p 76-82.
4. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA, for the US Lamivudine Investigator Group. 1999. Lamivudine as initial treatment for chronic hepatitis B in patients from the United States. N Engl J Med 341:1256-1269.
5. Dusheiko G. 1998. Lamivudine treatment of chronic hepatitis B. Rev Med Virol 8:153-159.
6. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Tuttle JV, Miller WH, Condreay L, Averett DR, Schinazi RF, Painter GR. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36: 2686-2692.
7. Goodman Z, Dhillon AP, Wu PC, Gray F, Atkins M, Stevenson C, Barber J, Brown N, Crowther L, Woessner M. 1999. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 30:59 (Abstract GS5/26).
8. Gust ID. 1996. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38(Suppl 2):S18-S23.
9. International Interferon-Alpha Hepatocellular Carcinoma Study Group. 1998. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351:1535-1539.
10. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
11. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
12. Lai CL. 1999. Antiviral therapy for hepatitis B and C in Asians. J Gastroenterol Hepatol 14(Suppl):S19-S21.
13. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, Dent JC, Edmundsen S, Liaw YF. 1999. Three year lamivudine therapy in chronic HBV. J Hepatol 30:59 (Abstract GS5/25).
14. Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Roman LC, Dent JC, Gray DF. 1998. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia. Gastroenterology 114:A1289 (Abstract L0375).
15. Pessoa MG, Wright TL. 1999. Update on clinical trials in the treatment of hepatitis B. J Gastroenterol Hepatol 14(Suppl):S6-S11.
16. Schalm SW, Heathcote J, Cianciara J, Farrell G, Shermann M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF, on behalf of an International Lamivudine Study Group. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46:562-568.
17. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. 1998. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28:388A (Abstract 901).
18. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray FD, and the Lamivudine Precore Mutant Study Group. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
19. Zuckerman AJ. 1996. Progress towards the comprehensive control of hepatitis B. Gut 38(Suppl 2):S1.
20. Zuckerman AJ. 1999. More than third of world's population has been infected with hepatitis B virus [letter]. Br Med J 318:1213.